Novo Nordisk had a record-breaking 2021 profit, but has reined in expectations for 2022

In 2021, Novo Nordisk has lifted both its revenue and profits to new heights, driven by great progress of its diabetes flagship semaglutide in both tablet and injection form. There are challenges ahead, however, the company warns, as it predicts less progress in 2022.

Photo: Stine Tidsvilde

2021 was a historically good year for Novo Nordisk, which has never achieved such high revenue and profit results before, the company’s full-year report, released on Wednesday morning, states.

For the fourth quarter of 2021, Novo Nordisk can present net profits of DKK 10.9bn (USD 1.65bn), which brings the full year’s profits up to DKK 47.8bn (USD 7.2bn) compared to 2020’s DKK 42.1bn (USD 6.4bn). That is a 14 percent increase at constant exchange rates (CER), according to the report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs